11.47
+0.07
+(0.61%)
At close: April 15 at 4:00:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
4,526,253
4,526,253
837,656
225,626
--
Cost of Revenue
133,248
133,248
94,117
31,259
--
Gross Profit
4,393,005
4,393,005
743,539
194,367
--
Operating Expense
2,226,181
2,226,181
1,965,561
1,460,801
952,423
Operating Income
2,166,824
2,166,824
-1,222,022
-1,266,434
-952,423
Net Non Operating Interest Income Expense
32,746
32,746
-21,318
3,884
26,518
Pretax Income
1,942,525
1,942,525
-1,422,216
-1,258,126
-1,320,579
Tax Provision
174
174
--
--
--
Net Income Common Stockholders
2,028,300
2,028,300
-1,168,393
-1,074,933
-1,036,374
Diluted NI Available to Com Stockholders
2,028,300
2,028,300
-1,168,393
-1,074,933
-1,036,374
Basic EPS
2.42
2.42
-1.42
-1.32
-1.65
Diluted EPS
2.42
2.42
-1.42
-1.32
-1.65
Basic Average Shares
837,683.78
837,683.78
824,989.86
815,931.80
628,941.61
Diluted Average Shares
837,821.48
837,821.48
824,989.86
815,931.80
628,941.61
Rent Expense Supplemental
2,683
--
--
--
--
Total Expenses
2,359,429
2,359,429
2,059,678
1,492,060
952,423
Net Income from Continuing & Discontinued Operation
2,028,300
2,028,300
-1,168,393
-1,074,933
-1,177,051
Normalized Income
1,976,198.67
1,976,198.67
-1,174,497
-1,083,455
-1,184,074
Interest Income
119,733
119,733
21,972
14,236
34,505
Interest Expense
86,987
86,987
43,290
10,352
7,987
Net Interest Income
32,746
32,746
-21,318
3,884
26,518
EBIT
2,029,512
2,029,512
-1,378,926
-1,247,774
-1,312,592
EBITDA
2,172,280
2,172,280
-1,273,137
-1,189,531
-1,290,485
Reconciled Cost of Revenue
133,248
133,248
94,117
31,259
--
Reconciled Depreciation
142,768
142,768
105,789
58,243
22,107
Net Income from Continuing Operation Net Minority Interest
2,028,300
2,028,300
-1,168,393
-1,074,933
-1,177,051
Total Unusual Items Excluding Goodwill
52,106
52,106
6,104
8,522
7,023
Total Unusual Items
52,106
52,106
6,104
8,522
7,023
Normalized EBITDA
2,120,174
2,120,174
-1,279,241
-1,198,053
-1,297,508
Tax Rate for Calcs
0
0
--
--
--
Tax Effect of Unusual Items
4.67
4.67
--
--
--
12/31/2020 - 5/17/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CGON CG Oncology, Inc.
20.22
+0.55%
ZBIO Zenas BioPharma, Inc.
8.33
-4.47%
TIL Instil Bio, Inc.
15.30
-7.16%
ACLX Arcellx, Inc.
60.69
-1.20%
MLYS Mineralys Therapeutics, Inc.
13.50
-2.74%
BV3A.F Bavarian Nordic A/S
6.65
0.00%
B9A.BE BioArctic AB
19.00
+14.46%
ZVA.F Cellectis S.A.
1.3180
-4.22%
1AEA.SG argenx SE
505.00
-3.81%
BV3.BE Bavarian Nordic A/S
20.15
-0.30%